Reminyl, Galantamine

Reminyl, Galantamine Newswire

Comprehensive Real-Time News Feed for Reminyl, Galantamine (generic).

Results 1 - 16 of 16 in Reminyl, Galantamine (generic)

  1. memantine, Namenda, Namenda XRRead the original story w/Photo

    Tuesday Feb 24 | MedicineNet

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

    Comment?

  2. AB Science : Successful Completion Of Futility Test For Masitinib In Alzheimer's DiseaseRead the original story

    Monday Feb 9 | BioSpace

    AB Science SA , a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors , today announced the successful completion of a futility analysis related to the masitinib phase 3 trial for the treatment of mild to moderate Alzheimer's disease. Based on these results, the Independent Data Safety Monitoring Committee has recommended the continuation of the study.

    Comment?

  3. Holy moly? Snowdrops, like these at Colesbourne Park, may be the medicinal herb cited by HomerRead the original story w/Photo

    Thursday Feb 5 | Oxford Times

    They may only be a few inches high, with tiny white flowers, but snowdrops cause great excitement in February. They welcome in spring, albeit early spring, and we can't wait to get among them in February.

    Comment?

  4. Pharmacological treatments for frontotemporal dementias: a systematic ...Read the original story

    Dec 29, 2014 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. The objective of this review is to summarize the current data on the pharmacological treatments for frontotemporal dementias from randomized controlled trials.

    Comment?

  5. ENTREVESTOR: P.E.I. firm gains traction with drugRead the original story w/Photo

    Dec 18, 2014 | The Chronicle Herald

    Denis Kay has been a scientist for a long time, but he's most thrilled by his current role working on a promising drug for Alzheimer's disease. Alzheimer's is an escalating problem in aging societies.

    Comment?

  6. Cholinergic Stimulation Enhances Bayesian Belief Updating in the Deployment of Spatial AttentionRead the original story

    Nov 23, 2014 | CiteULike

    The Journal of Neuroscience , Vol. 34, No. 47. , pp. 15735-15742, doi:10.1523/jneurosci.0091-14.2014 To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  7. Thousands 'too ashamed' to tell family or doctors they have...Read the original story w/Photo

    Oct 26, 2014 | Daily Mail

    Thousands 'too ashamed' to tell family or doctors they have dementia: Report compares stigma to that of HIV in the 1980s It compares the stigma to that of HIV and Aids in the 1980s and says as many as a quarter of those suffering are refusing to speak out. Doctors say patients tell them how their friends 'disappeared' after they were diagnosed and in some cases how their own children have stopped visiting.

    Comment?

  8. Hyderabad scientist elected as fellow of Indian National Science AcademyRead the original story w/Photo

    Oct 24, 2014 | DNA India

    The Indian National Science Academy , apex body of Indian scientists, has elected Chief Scientist of CSIR-IICT, Srivari Chandrasekhar, as a fellow from the year 2015. The recognition has been accorded for his contribution in the area of organic chemistry for the last two decades, according to a statement from CSIR-IICT .

    Comment?

  9. Neurotrope Tackles Alzheimer's Disease With Novel MechanismRead the original story w/Photo

    Oct 20, 2014 | Seeking Alpha

    Bryostatin-1 activates protein kinase C and represents a novel treatment option for AD that is supported by extensive preclinical data. Neurotrope has a basic market capitalization of only $14 million, with $10+ million in cash in the bank and data from a Phase 2a study coming in early 2015.

    Comment?

  10. Positive Phase 1a Outcome For Memogain??Read the original story

    Sep 9, 2014 | BioSpace

    Neurodyn Life Sciences Inc. announced completion of its first-in-human clinical study, demonstrating Memogain's potential benefits over existing Alzheimer's drugs; * increased safety in the absence of significant side effects, * more potent cognitive enhancement. The Phase IA clinical trial addressed safety, tolerability, and pharmacokinetics of intranasally delivered MemogainA in healthy young and elderly subjects, compared to the daily recommended doses of the current Alzheimer's drugs: galantamine and donepezil .

    Comment?

  11. Positive Phase 1a Outcome for MemogainRead the original story

    Sep 9, 2014 | Customer Interaction Solutions

    Neurodyn Life Sciences Inc. announced completion of its first-in-human clinical study, demonstrating Memogain's potential benefits over existing Alzheimer's drugs; The Phase IA clinical trial addressed safety, tolerability, and pharmacokinetics of intranasally delivered Memogain in healthy young and elderly subjects, compared to the daily recommended doses of the current Alzheimer's drugs: galantamine and donepezil . Study participants were additionally tested for improved cognition.

    Comment?

  12. Use of cognitive enhancers for mild cognitive impairment: protocol...Read the original story

    Aug 17, 2014 | CiteULike

    Elderly individuals who have memory problems without significant limitations in activities of daily living are often diagnosed as having mild cognitive impairment .

    Comment?

  13. Galantamine for Alzheimer's disease and mild cognitive impairment.Read the original story

    Aug 13, 2014 | CiteULike

    Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor.

    Comment?

  14. Proneurogenic Group II mGluR antagonist improves learning and reduces ...Read the original story

    Aug 12, 2014 | Molecular Psychiatry

    Correspondence: Dr S Gandy, James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, NY 10468, USA.

    Comment?

  15. 3.5 million for Exeter team's national health technology assessment workRead the original story w/Photo

    Aug 1, 2014 | Mid Devon Star

    A TEAM at the University of Exeter Medical School has been awarded A 3.5 million to continue providing high-quality evidence to help the National Institute for Health and Care Excellence form key decisions on healthcare.

    Comment?

  16. 3.5 million for Exeter team's national health technology assessment workRead the original story w/Photo

    Jul 30, 2014 | Mid Devon Star

    A TEAM at the University of Exeter Medical School has been awarded A 3.5 million to continue providing high-quality evidence to help the National Institute for Health and Care Excellence form key decisions on healthcare.

    Comment?